Gathering the record
Relay is organizing the evidence and source boundaries.
Topical cosmetic octapeptide
A cosmetic peptide used in some skin products and discussed for expression lines and wrinkles.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Small topical or multi-ingredient cosmetic studies report appearance changes, but they do not isolate SNAP-8 reliably.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
Relay has not verified a clear pattern of side effects for this compound.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryCosmetic ingredient; not FDA-approved as a drug for wrinkle treatment. The magnitude and durability of any independent topical effect, skin penetration, optimal formulation, and comparative performance.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Commercial cosmetic inclusion percentages are not necessarily active-peptide concentrations. A complete primary human concentration-and-application regimen was not verified.
What would fill this gap: A controlled primary report specifying active SNAP-8 concentration, vehicle, application amount, and duration.
Dosing review checked Oct 20, 2026. Additional sources are available below.No route-specific preparation instructions were verified. A different route or product does not supply them.
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
Published cosmetic research included SNAP-8 within multi-ingredient topical products, but the reviewed studies did not isolate the peptide's independent effect.
Population: No directly studied human population was verified for this identity.
Design: Small controlled multi-component cosmetic studies
No direct primary administration source was verified for this exact identity.
Mechanisms
The proposed mechanism involves modulating SNARE-complex-related neurotransmitter release near the skin surface. Direct independent clinical evidence is limited and often embedded in multi-ingredient formulations.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Research reference
A reference for the studies, populations, and routes behind this profile.
Limited topical and multi-ingredient cosmetic evidence; no injected-human evidence.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
The magnitude and durability of any independent topical effect, skin penetration, optimal formulation, and comparative performance.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
Standalone SNAP-8 clinical evidence: amounts and schedules describe this route record only.
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Co-ingredients and delivery systems prevent attribution of an outcome to SNAP-8. The section remains incomplete because a controlled standalone clinical administration record was not located. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Controlled cosmetic study
Adults with facial wrinkles
A small controlled study of a multi-ingredient peptide patch reported changes in facial-wrinkle measures.
Study administration: Multi-ingredient peptide microneedle patch
Limitations: Multi-ingredient product; cannot attribute effects specifically to SNAP-8.
Small controlled cosmetic study
Population not stated.
Endpoints were not fully described in the current record.
A multi-peptide topical delivery study reported cosmetic skin outcomes.
Study administration: Not stated in the current record.
Limitations: Small and multi-component; does not isolate SNAP-8.
Narrative review
Population not stated.
Endpoints were not fully described in the current record.
The review identifies a wider marketing base than direct high-quality clinical evidence for many cosmetic peptides.
Study administration: Not stated in the current record.
Limitations: Product and ingredient evidence varies; review does not establish independent efficacy.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 39082657
PMID 31134751
PMID 33117776